For the quarter ending 2025-12-31, FUNI had -$51,290 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net cash (used in) operating activities from continuing operations | - | -315,063 | -64,912 |
| Net cash provided by operating activities from discontinued operations | - | 0 | 0 |
| Gain on sale of subsidiary assets | - | 0 | - |
| Net loss from continuing operations | -521,638 | -558,415 | -2,543,486 |
| Loss on debt extinguishment | - | -32,347 | 0 |
| Stock-based compensation | 218,131 | 112,682 | 1,737,478 |
| Gain on sale of subsidiary net assets | - | - | 0 |
| Amortization of debt discounts | 15,926 | 2,132 | 0 |
| Depreciation expense | 2,023 | 3,235 | 7,583 |
| Amortization of right-of-use asset | 9,653 | 30,826 | 21,366 |
| Other current assets | - | -13,596 | -248,868 |
| Prepaids and other current assets | -8,380 | - | - |
| Accounts payable | 74,323 | -30,946 | 399,715 |
| Accrued expenses | 23,679 | 39,992 | 56,307 |
| Accrued expenses related parties | 29,174 | 70,561 | 33,978 |
| Lease liability | -9,899 | -9,707 | -26,721 |
| Net cash used in operating activities | -150,248 | -315,063 | -64,912 |
| Proceeds from convertible notes | - | 63,000 | 130,000 |
| Net cash (used) in investing activities from discontinued operations | - | 0 | 0 |
| Payments of deferred offering costs | - | -16,289 | 123,032 |
| Proceeds from sale of subsidiary net assets | - | 0 | 0 |
| Proceeds from sales of series d preferred shares | - | 76,296 | - |
| Purchase of fixed assets | - | 31,236 | 1,730 |
| Proceeds from sales of series c preferred shares | - | 0 | 100 |
| Net cash (used) in investing activities from continuing operations | - | -31,236 | -1,730 |
| Net Cash Provided By Used In Financing Activities Continuing Operations | - | 237,225 | 122,668 |
| Net cash (used) in investing activities | - | -31,236 | -1,730 |
| Net cash used in financing activities from discontinued operations | - | 0 | 0 |
| Repayments of notes payable | - | 0 | 0 |
| Repayments on convertible notes | - | 0 | 0 |
| Proceeds from notes payable | 97,500 | 81,640 | 115,600 |
| Proceeds from sale of series d preferred shares and warrants, net of fees | 57,484 | - | - |
| Net cash provided by (used in) financing activities | 154,984 | 237,225 | 122,668 |
| Net increase (decrease) in cash | -51,290 | -53,048 | 56,026 |
| Cash and cash equivalents at beginning of period | 38,118 | 91,166 | - |
| Cash and cash equivalents at end of period | 42,854 | 38,118 | - |
Hypha Labs, Inc. (FUNI)
Hypha Labs, Inc. (FUNI)